Overview

• Patients on 2 mg baxdrostat added to standard care achieved a statistically significant systolic reduction versus placebo at 12 weeks.
• Baxdrostat lowered blood pressure across a full 24-hour period, including the early morning window when cardiovascular events are more common.
• The therapy blocks aldosterone production and is also under study for chronic kidney disease and prevention of heart failure.
• AstraZeneca has guided to a regulatory submission before the end of 2025 and has cited potential peak annual sales above $5 billion.
• Rival developer Mineralys plans to submit data for its aldosterone-targeting drug lorundrostat to U.S. regulators by year-end, with full baxdrostat results slated for presentation at an American Heart Association meeting in November.